Removing Foxp3+Treg cells from tumor tissues can enhance anti-tumor immunity, hence a combined strategy of blocking PD-L1/PD-1 while depleting Tregs might show promise in improving treatment outcomes for these patients. The gene discussed is PDCD1; the disease is neoplasm.